司美格鲁肽的使用，推动了长期被忽视病症的诊断

Core Viewpoint - The rise of GLP-1 receptor agonists (GLP-1 RAs) is transforming the healthcare landscape, with significant adoption among the population, particularly for treating obesity and cardiovascular diseases in addition to type 2 diabetes [2][4]. Group 1: Research Methodology - Truveta's study included patients who received their first GLP-1 RA prescription between January 2018 and October 2024, focusing on those with a BMI over 27, indicating overweight or obesity [6]. - The study analyzed the percentage of patients diagnosed with type 2 diabetes (T2D), cardiovascular disease (CVD), or sleep apnea within 15 days of their first GLP-1 RA prescription, particularly in the overweight/obese categories [6]. Group 2: First Prescription Rates - The percentage of new diagnoses within 15 days of the first GLP-1 prescription increased with the severity of obesity, with rates for T2D, CVD, and sleep apnea documented [7]. - The rates of new diagnoses were as follows: Overweight (2.5% T2D, 1.4% CVD, 0.5% sleep apnea), Obesity Class 1 (3.3% T2D, 1.4% CVD, 0.8% sleep apnea), Obesity Class 2 (3.9% T2D, 1.4% CVD, 1.1% sleep apnea), and Obesity Class 3 (5.1% T2D, 1.4% CVD, 1.5% sleep apnea) [8]. Group 3: Trends Over Time - The rate of first CVD diagnoses increased by 14.3% from 2020 to 2024, with a notable increase of 34.5% among overweight individuals [10]. - The incidence of sleep apnea diagnoses rose by 34%, from 0.8% in 2020 to 1.1% in 2024, with the highest increase seen in Obesity Class 1 [11]. - The prevalence of T2D diagnoses increased from 3.2% in 2020 to 4.2% in 2024, marking a 31.6% rise, with the increase correlating with higher obesity classes [12]. Group 4: Summary - The study provides insights into the evolving role of GLP-1 RAs in healthcare, particularly their potential as catalysts for early diagnosis and intervention in metabolic and related diseases among overweight or obese populations [14].